Compare BLFY & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLFY | FULC |
|---|---|---|
| Founded | 1939 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.3M | 468.1M |
| IPO Year | N/A | 2019 |
| Metric | BLFY | FULC |
|---|---|---|
| Price | $12.54 | $12.93 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $10.00 | ★ $16.38 |
| AVG Volume (30 Days) | 290.5K | ★ 2.6M |
| Earning Date | 01-28-2026 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $44,731,000.00 | N/A |
| Revenue This Year | $19.85 | N/A |
| Revenue Next Year | $20.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 11.52 | ★ 2752.05 |
| 52 Week Low | $7.61 | $2.32 |
| 52 Week High | $12.73 | $15.74 |
| Indicator | BLFY | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 83.06 | 61.65 |
| Support Level | $11.93 | $12.56 |
| Resistance Level | $12.73 | $15.32 |
| Average True Range (ATR) | 0.36 | 1.27 |
| MACD | 0.15 | 0.30 |
| Stochastic Oscillator | 93.62 | 60.90 |
Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.